問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Chi Mei Medical Center (在職)

Division of Hematology & Oncology

Chi Mei Hospital, Liouying (在職)

Division of Hematology & Oncology

Chi Mei Medical Center (在職)

Division of Hematology & Oncology

Chi Mei Medical Center (在職)

Division of Hematology & Oncology

更新時間：2023-09-19

郭雨萱
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

65Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

郭雨萱

List

87Cases

2023-08-01 - 2036-12-31

Phase III

CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence

  • Condition/Disease

    Breast Cancer, Early Breast Cancer

  • Test Drug

    Camizestrant (AZD9833)

Participate Sites
8Sites

Recruiting8Sites

2023-12-31 - 2025-12-31

Phase III

CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease

  • Condition/Disease

    Breast Cancer, Early Breast Cancer

  • Test Drug

    Camizestrant (AZD9833)

Participate Sites
8Sites

Recruiting8Sites

2018-01-01 - 2022-12-31

Phase III

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane

  • Condition/Disease

    HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane

  • Test Drug

    Tesetaxel

Participate Sites
7Sites

Terminated7Sites

趙大中
Taipei Veterans General Hospital

陳訓徹
Linkou Chang Gung Medical Foundation

Division of General Surgery

2017-08-10 - 2021-06-30

Phase III

A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma

  • Condition/Disease

    Esophageal Squamous Cell Carcinoma

  • Test Drug

    Nivolumab/Ipilimumab

Participate Sites
15Sites

Terminated13Sites

林振源
China Medical University Hospital-Taipei

未分科

陳明晃
Taipei Veterans General Hospital

Division of Hematology & Oncology

2013-08-01 - 2020-06-30

Phase III

A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting (NALA)

  • Condition/Disease

    HER2+ Metastatic Breast Cancer(MBC)

  • Test Drug

    Neratinib

Participate Sites
16Sites

Terminated16Sites

2015-12-01 - 2026-12-31

Phase II

A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158)

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    Pembrolizumab (MK-3475)

Participate Sites
8Sites

Recruiting8Sites

2020-08-01 - 2025-04-07

Phase III

A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer

  • Condition/Disease

    Metastatic Castration-Resistant Prostate Cancer

  • Test Drug

    Cabometyx; Tecentriq; Zytiga; Xtandi; Prednisone

Participate Sites
8Sites

Recruiting4Sites

Terminated4Sites

2019-06-01 - 2025-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-04-01 - 2025-12-31

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2022-03-01 - 2027-08-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting12Sites

1 5 6 7 8 9
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB